Form Bio is a technology company.
Form Bio has raised $30.5M across 2 funding rounds.
Form Bio has raised $30.5M in total across 2 funding rounds.
# Form Bio: AI-Powered Genetic Medicine Platform
Form Bio is a computational life sciences company that develops AI and software solutions for cell and gene therapy development.[1][2] Founded in 2022 as a spinout from Colossal Biosciences, the company provides drug developers with tools to accelerate the preclinical development stage—from early design through manufacturing and regulatory submission.[3]
The company serves biopharma companies, contract research organizations, and academic institutions working on genetic medicines. Form Bio's core offering is its FORMsight AI platform, which enables rapid in silico characterization, prediction, simulation, and optimization of therapeutics.[3] By automating computational workflows that traditionally required extensive manual effort, Form Bio helps customers reduce development timelines, lower costs, and improve therapeutic safety and efficacy. The company has demonstrated tangible impact: its platform delivers up to 5x improvements in genome integrity and 4.4x yield gains in manufacturing, directly reducing cost of goods sold (COGS).[1]
Form Bio emerged from the computational needs of Colossal Biosciences, a synthetic biology company co-founded by Harvard geneticist George Church.[5] Co-founders Kent Wakeford and Andrew Busey recognized that Colossal's cutting-edge CRISPR gene editing work required sophisticated computational and algorithmic support—tools to predict outcomes, validate results, and accelerate the path from concept to execution.[5] Rather than keep this capability internal, they saw an opportunity to serve the broader synthetic biology ecosystem. In 2022, they spun out Form Bio as an independent company based in Austin, Texas, raising capital and building a multidisciplinary team of AI engineers, bioinformaticians, molecular biologists, and drug developers.[1][3]
This origin story is significant: Form Bio was born from real scientific pain points, not theoretical market analysis. The founders understood firsthand what genetic medicine developers needed because they were solving those problems for Colossal.
Form Bio's proprietary FORMsight AI model optimizes AAV vector genomes and complex payloads, improving genome integrity, reducing truncations, and enabling tunable expression.[1] The platform uses AI-augmented coding sequence (CDS) optimization and rational design to enhance manufacturability and lower safety risks, including reducing CpG-driven immunogenicity.[1]
Rather than offering point solutions, Form Bio provides a comprehensive cloud-based bioinformatics platform that integrates data management, workflows, results visualization, and collaboration.[5] The platform includes a verified catalog of workflows spanning ancient DNA analysis, transcriptomics, and AAV gene therapy, making it accessible to non-technical bench scientists.[5][6]
Form Bio doesn't just optimize designs—it validates them. The company offers Long-read AAV Analysis (LAAVA) software for comprehensive genome integrity characterization and partners with synthesis providers like GENEWIZ to streamline the entire workflow from design through sequencing and packaging.[2] This end-to-end approach directly reduces time and cost to reach lead candidates.
Form Bio is a Google Cloud Premier Partner and natively built on Google Cloud infrastructure.[6] This partnership enables customers to access Google Cloud's Vertex AI-based omics models through point-and-click workflows, democratizing access to advanced AI capabilities.[6]
Form Bio operates at the intersection of three powerful trends: AI-driven drug discovery, synthetic biology acceleration, and the shift toward computational-first development.
The genetic medicine field has historically been bottlenecked by the preclinical development stage—the lengthy period between initial discovery and clinical readiness where manual optimization, validation, and manufacturing scale-up consume years and millions of dollars.[3] While AI has already transformed early drug discovery and target identification, the preclinical stage remained largely manual and empirical. Form Bio directly addresses this gap, positioning itself as a "comprehensive in silico partner" that bridges discovery and clinical translation.[3]
The timing is critical. AAV gene therapy is experiencing explosive growth as a therapeutic modality, with dozens of programs in clinical development. Simultaneously, CRISPR and next-generation genome editing technologies are maturing, creating demand for better design and validation tools. Form Bio's platform arrives as the field scales, offering a way to reduce development risk and accelerate time-to-market—both critical competitive advantages in a capital-intensive industry.
By embedding AI into the workflows of drug developers, Form Bio influences how genetic medicines are designed and manufactured across the entire ecosystem. Its partnerships with infrastructure providers like GENEWIZ and cloud platforms like Google Cloud amplify this influence, making its tools increasingly central to industry workflows.
Form Bio is well-positioned to become the standard computational platform for genetic medicine development. The company has solved a real problem—accelerating preclinical development through AI—with measurable results (4.4x yield improvements, 5x genome integrity gains). Its origin from Colossal Biosciences provides both credibility and a built-in customer, while its Google Cloud partnership offers distribution and infrastructure advantages.
Looking ahead, Form Bio's growth will likely track the expansion of the genetic medicine market itself. As more programs enter clinical development and manufacturing scales, demand for tools that reduce costs and improve safety will intensify. The company's ability to expand beyond AAV vectors into other modalities (lipid nanoparticles, viral vectors, cell therapies) will determine whether it remains a niche tool or becomes a foundational platform.
The broader trend favoring Form Bio: the biotech industry is increasingly recognizing that computational advantage—the ability to design better therapeutics faster and cheaper—is as important as wet-lab capability. Form Bio is betting that this shift will make AI-powered design and optimization indispensable, not optional.
Form Bio has raised $30.5M in total across 2 funding rounds.
Form Bio's investors include Acrew Capital, Bonfire Ventures, Canaan Partners, Jazz Venture Partners, Precursor Ventures, Deborah Liu, Jeffrey Wilke, KittyHawk Ventures, Ulu Ventures.
Form Bio has raised $30.5M across 2 funding rounds. Most recently, it raised $30.0M Series A in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $30.0M Series A | Acrew Capital, Bonfire Ventures, Canaan Partners, Jazz Venture Partners, Precursor Ventures, Deborah Liu, Jeffrey Wilke | |
| Jun 1, 2022 | $500K Seed | KittyHawk Ventures, Ulu Ventures |